Guangdong Walvax Pharmaceuticals Technology Co., Ltd. announced that it will receive CNY 110,000,000 in an equity round of funding on September 14, 2021. The transaction will include participation from returning investor Walvax Biotechnology Co., Ltd., which will retain its 100% stake in the company. The transaction has been approved by the 24th meeting of the 2021 President’s Office. Post transaction, the registered capital will increase from CNY 110,000,000 to CNY 220,000,000.